{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:15:07Z","timestamp":1768569307860,"version":"3.49.0"},"posted":{"date-parts":[[2025,5,28]]},"group-title":"Epidemiology","reference-count":41,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,5,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Home antiviral treatment (HAVT: nirmatrelvir\/ritonavir [Paxlovid] and molnupiravir [Lagevrio]) for COVID-19 was approved in December 2021 by the U.S. Food and Drug Administration, but ensuing utilization during the COVID-19 pandemic was low. Factors associated with seeking HAVT treatment have not been fully explored.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Study Design<\/jats:title>\n                  <jats:p>Cross-sectional survey of 9,944 U.S. adults to identify factors associated with seeking and receiving HAVT in persons with confirmed or suspected COVID-19.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>COVID-19 infection was confirmed or suspected in 4,355 (43.8%) participants. HAVT was sought by 1,331 (26.3%) and medication was received by 928 (20.7%). In comparison to those who were COVID-19 test negative and had no loss of taste or smell (aOR: 1.856, 95% C.I.: 1.262-2.728), the factor most associated with seeking HAVT was a loss of taste or smell irrespective of a positive (aOR: 3.823, 95% C.I.: 2.626-5.567) or negative COVID-19 test (aOR: 3.306; 95% C.I.: 2.086-5.241). Loss of taste or smell was similarly associated with receiving HAVT. Male sex, younger age, Black race, Hispanic ethnicity, conservative or liberal political preference, and medical discrimination were some of the other factors associated with a greater likelihood of seeking HAVT. Barriers to obtaining treatment included feeling uncomfortable obtaining HAVT while sick and lack of transportation; 14.7% of those seeking treatment reported at least one barrier.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In a general population, HAVT was an underutilized resource during the COVID-19 pandemic. Loss of taste or smell was the most important factor among several others associated with seeking HAVT irrespective of COVID-19 test status.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.05.25.25328310","type":"posted-content","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T01:20:20Z","timestamp":1748481620000},"source":"Crossref","is-referenced-by-count":0,"title":["Factors Associated with Seeking and Receiving Home Antiviral Therapy During the COVID-19 Pandemic"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9474-7679","authenticated-orcid":false,"given":"Stuart F.","family":"Quan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3578-336X","authenticated-orcid":false,"given":"Matthew D.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark \u00c9.","family":"Czeisler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0533-3715","authenticated-orcid":false,"given":"Lauren A.","family":"Booker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-1496","authenticated-orcid":false,"given":"Mark E.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4976-8101","authenticated-orcid":false,"given":"Melinda L.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6481-3391","authenticated-orcid":false,"given":"Christine F.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1360-9387","authenticated-orcid":false,"given":"Anna","family":"Ridgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0288-2505","authenticated-orcid":false,"given":"Rebecca","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5408-1625","authenticated-orcid":false,"given":"Prerna","family":"Varma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7527-8558","authenticated-orcid":false,"given":"Shantha M.W.","family":"Rajaratnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7408-1849","authenticated-orcid":false,"given":"Charles A.","family":"Czeisler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025053006500460000_2025.05.25.25328310v1.1","unstructured":"Prioritization of Anti-SARS-CoV-2 Therapies for the Treatment of COVID-19 in Nonhospitalized Patients When There Are Logistical Constraints 2022."},{"key":"2025053006500460000_2025.05.25.25328310v1.2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac180"},{"key":"2025053006500460000_2025.05.25.25328310v1.3","unstructured":"Choi J. Biden announces \u2018Test to Treat\u2019 initiative, free COVID-19 antiviral treatment after positive test. The Hill 2022. https:\/\/thehill.com\/policy\/healthcare\/596449-biden-announces-test-to-treat-initiative-free-covid-19-antiviral-treatment\/ (accessed April 3, 2025)."},{"key":"2025053006500460000_2025.05.25.25328310v1.4","unstructured":"Dunleavy K. FDA will allow pharmacists to provide Pfizer\u2019s Paxlovid pills 2022. https:\/\/www.fiercepharma.com\/pharma\/allowing-pharmacists-prescribe-pfizers-paxlovid-should-ease-access-covid-19-oral-antiviral (accessed April 3, 2025)."},{"key":"2025053006500460000_2025.05.25.25328310v1.5","unstructured":"Hill L , Artiga S , Rouw A , Published JK . How Equitable is Access to COVID-19 Treatments? KFF 2022. https:\/\/www.kff.org\/coronavirus-covid-19\/issue-brief\/how-equitable-is-access-to-covid-19-treatments\/ (accessed April 3, 2025)."},{"key":"2025053006500460000_2025.05.25.25328310v1.6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac443"},{"key":"2025053006500460000_2025.05.25.25328310v1.7","doi-asserted-by":"publisher","DOI":"10.7326\/M22-3057"},{"key":"2025053006500460000_2025.05.25.25328310v1.8","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2023.01641"},{"key":"2025053006500460000_2025.05.25.25328310v1.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57633-7"},{"key":"2025053006500460000_2025.05.25.25328310v1.10","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00910-1"},{"key":"2025053006500460000_2025.05.25.25328310v1.11","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7143a2"},{"key":"2025053006500460000_2025.05.25.25328310v1.12","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.5044"},{"key":"2025053006500460000_2025.05.25.25328310v1.13","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7303a2"},{"key":"2025053006500460000_2025.05.25.25328310v1.14","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7125e1"},{"key":"2025053006500460000_2025.05.25.25328310v1.15","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-022-07844-3"},{"key":"2025053006500460000_2025.05.25.25328310v1.16","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7103e1"},{"key":"2025053006500460000_2025.05.25.25328310v1.17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.34147"},{"key":"2025053006500460000_2025.05.25.25328310v1.18","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19687-0"},{"key":"2025053006500460000_2025.05.25.25328310v1.19","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000002570"},{"key":"2025053006500460000_2025.05.25.25328310v1.20","doi-asserted-by":"publisher","DOI":"10.1093\/tbm\/ibaa090"},{"key":"2025053006500460000_2025.05.25.25328310v1.21","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7216a5"},{"key":"2025053006500460000_2025.05.25.25328310v1.22","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.10588"},{"key":"2025053006500460000_2025.05.25.25328310v1.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2004.21146.x"},{"key":"2025053006500460000_2025.05.25.25328310v1.24","first-page":"502","article-title":"Adapting the everyday discrimination scale to medical settings: reliability and validity testing in a sample of African American patients","volume":"21","year":"2011","journal-title":"Ethn Dis"},{"key":"2025053006500460000_2025.05.25.25328310v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2023.04.002"},{"key":"2025053006500460000_2025.05.25.25328310v1.26","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5869"},{"key":"2025053006500460000_2025.05.25.25328310v1.27","unstructured":"What doctors wish patients knew about COVID-19 oral antivirals. American Medical Association 2023. https:\/\/www.ama-assn.org\/delivering-care\/public-health\/what-doctors-wish-patients-knew-about-covid-19-oral-antivirals (accessed April 11, 2025)."},{"key":"2025053006500460000_2025.05.25.25328310v1.28","unstructured":"Adams B. Paxlovid for COVID ad Launched by Pfizer | Fierce Pharma 2023. https:\/\/www.fiercepharma.com\/marketing\/pfizer-launches-new-branded-paxlovid-ad-covid-it-continues-wait-fda-approval (accessed April 11, 2025)."},{"key":"2025053006500460000_2025.05.25.25328310v1.29","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2023.01641"},{"key":"2025053006500460000_2025.05.25.25328310v1.30","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2020.01699"},{"key":"2025053006500460000_2025.05.25.25328310v1.31","unstructured":"McDonald J. Post Omits Paxlovid\u2019s Ability to Protect Against Severe COVID-19, Death. FactCheckOrg 2022. https:\/\/www.factcheck.org\/2022\/11\/scicheck-post-omits-paxlovids-ability-to-protect-against-severe-covid-19-death\/ (accessed April 4, 2025)."},{"key":"2025053006500460000_2025.05.25.25328310v1.32","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.3257"},{"key":"2025053006500460000_2025.05.25.25328310v1.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47199-3"},{"key":"2025053006500460000_2025.05.25.25328310v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00011-7"},{"key":"2025053006500460000_2025.05.25.25328310v1.35","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.839182"},{"key":"2025053006500460000_2025.05.25.25328310v1.36","doi-asserted-by":"publisher","DOI":"10.1002\/ohn.384"},{"key":"2025053006500460000_2025.05.25.25328310v1.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2023.104176"},{"key":"2025053006500460000_2025.05.25.25328310v1.38","unstructured":"Rabin RC . Lost Sense of Smell May Be Peculiar Clue to Coronavirus Infection. The New York Times 2020."},{"key":"2025053006500460000_2025.05.25.25328310v1.39","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7143a3"},{"key":"2025053006500460000_2025.05.25.25328310v1.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.paid.2021.111124"},{"key":"2025053006500460000_2025.05.25.25328310v1.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2006.00396.x"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.05.25.25328310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:36:56Z","timestamp":1768509416000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.05.25.25328310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1101\/2025.05.25.25328310","relation":{},"subject":[],"published":{"date-parts":[[2025,5,28]]},"subtype":"preprint"}}